We develop a multivariate cure survival model to estimate lifetime patterns of colorectal cancer screening. Screening data cover long periods of time, with sparse observations for each person. Some events may occur before the study begins or after the study ends, so the data are both left-censored and right-censored, and some individuals are never screened (the 'cured' population). We propose a multivariate parametric cure model that can be used with left-censored and right-censored data. Our model allows for the estimation of the time to screening as well as the average number of times individuals will be screened. We calculate likelihood functions based on the observations for each subject using a distribution that accounts for within-sub...
A significant proportion of patients in cancer clinical trials can be cured. That is, the symptoms o...
Historically, the cure rate model has been used for modeling time-to-event data within which a signi...
Due to significant progress in cancer treatments and management in survival studies involving time t...
The authors propose a novel class of cure rate models for right-censored failure time data. The clas...
Medical investigations nowadays allow the incorporation of cure individuals in the analysis, especia...
AbstractWe develop Bayesian methods for right censored multivariate failure time data for population...
In this paper we deal with a Bayesian analysis for right-censored survival data suitable for populat...
In population-based cancer studies, cure is said to occur when the mortality (hazard) rate in the di...
Multivariate longitudinal data frequently arise in biomedical applications, however their analysis, ...
In population based cancer clinical trials, a proportion of patients will never experience the inter...
In survival analysis it often happens that some subjects under study do not experience the event of ...
The paper is motivated by cure detection among the prostate cancer patients in the National Institut...
Middle censoring refers to data that becomes unobservable if it falls within a random interval (L,R)...
We consider the problem of estimating the distribution of time-to-event data that are subject to cen...
In survival studies, it is often of interest to study cure rates. Sometimes the event of interest (s...
A significant proportion of patients in cancer clinical trials can be cured. That is, the symptoms o...
Historically, the cure rate model has been used for modeling time-to-event data within which a signi...
Due to significant progress in cancer treatments and management in survival studies involving time t...
The authors propose a novel class of cure rate models for right-censored failure time data. The clas...
Medical investigations nowadays allow the incorporation of cure individuals in the analysis, especia...
AbstractWe develop Bayesian methods for right censored multivariate failure time data for population...
In this paper we deal with a Bayesian analysis for right-censored survival data suitable for populat...
In population-based cancer studies, cure is said to occur when the mortality (hazard) rate in the di...
Multivariate longitudinal data frequently arise in biomedical applications, however their analysis, ...
In population based cancer clinical trials, a proportion of patients will never experience the inter...
In survival analysis it often happens that some subjects under study do not experience the event of ...
The paper is motivated by cure detection among the prostate cancer patients in the National Institut...
Middle censoring refers to data that becomes unobservable if it falls within a random interval (L,R)...
We consider the problem of estimating the distribution of time-to-event data that are subject to cen...
In survival studies, it is often of interest to study cure rates. Sometimes the event of interest (s...
A significant proportion of patients in cancer clinical trials can be cured. That is, the symptoms o...
Historically, the cure rate model has been used for modeling time-to-event data within which a signi...
Due to significant progress in cancer treatments and management in survival studies involving time t...